DBS TaT in Peer-assisted Telemedicine for Hepatitis C
- Disease/Condition
- Hepatitis C
- Drug/Device/Intervention
- DBS TaT
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- Oregon Health and Science University
- Phase
- N/A
- Start date
- May 01, 2024
- End date
- May 01, 2026
- Enrollment
- 183 participants
HCV Treatment Initiation
The purpose of this study is to compare the rate of treatment initiation achieved by
 peer-assisted telemedicine contingent on phlebotomy (usual care) versus that achieved with a
 new protocol, called Dried Blood Spot Test and Treat (DBS TaT). DBS TaT includes DBS testing
 to diagnose hepatitis C (HCV), utilizes a novel clinical decision aid that identifies
 patients who are low risk for hepatic (liver) fibrosis, and directs those patients to HCV
 treatment initiation prior to routine hepatic fibrosis assessment.
 
 The investigators hypothesize that DBS TaT will increase the rate of HCV treatment initiation
 compared to peer-assisted telemedicine contingent on phlebotomy (usual care).
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06409169
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06409169 through Pure Global AI's free database. This phase not specified trial is sponsored by Oregon Health and Science University and is currently Not yet recruiting. The study focuses on Hepatitis C. Target enrollment is 183 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.